Stock Mover of the Day: Aralez Pharmaceuticals Inc Can’t Be More Risky. Trades Sigfnicicantly Lower

Stock Mover of the Day: Aralez Pharmaceuticals Inc Can't Be More Risky. Trades Sigfnicicantly Lower

The stock of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) is a huge mover today! About 520,968 shares traded hands. Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) has declined 19.16% since March 11, 2016 and is downtrending. It has underperformed by 24.62% the S&P500.
The move comes after 8 months negative chart setup for the $313.81 million company. It was reported on Oct, 14 by We have $4.18 PT which if reached, will make NASDAQ:ARLZ worth $40.80M less.

Analysts await Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) to report earnings on November, 14. They expect $-0.32 earnings per share, down 28.00% or $0.07 from last year’s $-0.25 per share. After $-0.27 actual earnings per share reported by Aralez Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 18.52% negative EPS growth.

According to Zacks Investment Research, “Aralez Pharmaceuticals Inc. is a global specialty pharmaceutical company. They acquire, develop and commercialize products primarily in cardiovascular, pain and other specialty areas.”

More notable recent Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) news were published by: which released: “Aralez Pharmaceuticals Inc (ARLZ) Soars on AstraZeneca Deal” on October 04, 2016, also with their article: “Why Aralez Pharmaceuticals Inc. Approved a Higher Price Today” published on September 15, 2016, published: “Why Aralez Pharmaceuticals Inc Jumped Higher Today” on August 01, 2016. More interesting news about Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) were released by: and their article: “/quotes/zigman/3870025/realtime” published on February 12, 2016 as well as‘s news article titled: “Aralez Pharmaceuticals Inc.: Upcoming Catalysts Create Tremendous Upside” with publication date: August 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment